INDV241115P20000
- 10.47
- 0.000.00%
Indivior Newsroom
Indivior Extends Board Tenure Amidst Shareholder Changes
Deerfield's Strategic Stake Acquisition in Indivior
M&A Deals Roundup: Blackstone, BCE, CrowdStrike, Danone and More
Indivior Shareholder Oaktree Capital Calls for Board Refresh
Indivior Engages With Oaktree on Value Proposals
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
Indivior Jumps Amid Takeover Speculation
Indivior Boosts Shareholder Value With Repurchase Program
Indivior Boosts Liquidity With $400 Million Refinancing
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Raises Target Price to $16
Earnings Call: Indivior PLC Reports Strong Q3 Revenue Growth, Eyes Expansion
Indivior PLC (INDV) Q3 2024 Earnings Call Transcript Summary
Indivior PLC (INDV) Q3 2024 Earnings Call Transcript
Indivior | 6-K: Report of foreign private issuer (related to financial reporting)
Earnings Preview: Indivior to Report Financial Results Pre-market on October 24
$Indivior(INDV.US)$ is scheduled to release its financial results pre-market on October 24 ET. Earnings PreviewAnalysts estimate $Indivior(INDV.US)$ to post revenue of USD302.80M for 2024Q3, up 11.73%
Indivior PLC Reports Strong Q3 2024 Performance
Indivior PLC Continues Aggressive Share Buyback
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Two Seas Capital LP Increases Stake in Indivior PLC
Analysts Offer Insights on Healthcare Companies: Indivior (GB:INDV), Vor Biopharma (VOR) and Allogene Therapeutics (ALLO)